Table 4. Prognostic factors according to overall survival in all patients.

	Univariate analyses
	Overall survival (all patients n=61)
	Evts/pts	HR	95% CI	P-valuea
Sex
Male vs female	39/61	1.19	0.62–2.30	0.61
Age in years
Continuous	39/61	0.98	0.96–1.00	0.06
>65 vs⩽65	39/61	0.65	0.32–1.32	0.23
WHO PS
2 vs 0–1	32/38	3.4	1.47–7.97	<0.01
Disease stage
Stage III vs stages I and II	37/59	1.20	0.45–3.24	0.72
Stage IV vs stages I and II	37/59	6.97	2.69–18.1	<0.001
Tumour differentiation
Poorly vs well and moderately	39/61	1.94	0.90–4.19	0.09
Primary site
Jejunum vs duodenum	39/61	0.85	0.38–1.86	0.68
Ileum vs duodenum	39/61	1.43	0.65–3.14	0.37
Quality of resection
R1 vs R0	34/56	2.60	0.88–7.71	0.08
R2 vs R0	34/56	2.65	1.05–6.69	0.04
Baseline CA19-9 (IU ml−1)
>37 vs⩽37	28/34	1.69	0.49–5.77	0.40
Baseline CEA (ng ml−1)
5 vs⩽5	33/40	0.92	0.32–2.65	0.88
βP53
Overexpression vs normal	38/60	0.92	0.48–1.80	0.82
β-Catenin
Abnormal vs normal	38/60	0.96	0.43–2.11	0.91
MMR phenotype
dMMR vs pMMR	38/59	0.29	0.10–0.85	0.02
KRAS status
Mutated vs wild	30/48	0.72	0.35–1.48	0.36

	Multivariate analyses
	Overall survival N=35, events=29C index=0.718, likelihood ratio test=22.97 for 4 df, P<0.0001
	HR	95% CI	P-value
WHO PS
2 vs 0–1	7.07	2.25–22.17	<0.001
Disease stage
Stage III vs stages I and II	0.92	0.22–3.89	0.90
Stage IV vs stages I and II	6.09	1.68–22.16	<0.01
MMR phenotype
dMMR vs pMMR	1.48	0.39–5.57	0.56

	Multivariate analyses excluding PS status
	Overall survival N=57, events=36C index=0.728, likelihood ratio test=26.26 for 3 df, P<0.0001
	HR	95% CI	P-value
Disease stage
Stage III vs stages I and II	1.51	0.53–4.33	0.44
Stage IV vs stages I and II	6.78	2.57–17.92	<0.001
MMR phenotype
dMMR vs pMMR	0.44	0.13–1.55	0.20

Abbreviations: CEA=carcinoembryonic antigen; CI=confidence interval; dMMR=mismatch repair deficiency; Evts=events; HR=hazard ratio; pMMR=proficient mismatch repair; PS=performance status; pts=patients; WHO=World Health Organisation.

^aLog-rank test.